T. Rowe Price Associates
MLYS icon

T. Rowe Price Associates’s Mineralys Therapeutics MLYS Stock Holding History

T. Rowe Price Associates’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.4M Buy
1,343,313
+18,193
+1% +$534K ﹤0.01% 872
2025
Q4 		$48.1M Buy
1,325,120
+1,303,737
+6,097% +$52.3M 0.01% 827
2025
Q3 		$811K Buy
21,383
+1,815
+9% +$39.3K ﹤0.01% 2154
2025
Q2 		$265K Buy
19,568
+7,151
+58% +$104K ﹤0.01% 2582
2025
Q1 		$198K Buy
12,417
+702
+6% +$8.07K ﹤0.01% 2643
2024
Q4 		$145K Buy
+11,715
New +$153K ﹤0.01% 2775

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

T. Rowe Price Associates's MLYS Position: Q1 2026 in Review

T. Rowe Price Associates increased its Mineralys Therapeutics (MLYS) stake by 1.4% in Q1 2026, buying an estimated $534K and bringing the position to 1,343,313 shares worth $36.4M. The position accounts for ﹤0.01% of the portfolio, ranked #872.

T. Rowe Price Associates first reported a position in MLYS in Q4 2024 and has held it in 6 quarters since. The position peaked at $48.1M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • T. Rowe Price Associates held 1,343,313 shares of Mineralys Therapeutics worth $36.4M as of Q1 2026.
  • T. Rowe Price Associates bought 18,193 Mineralys Therapeutics shares in Q1 2026, an estimated $534K.
  • Mineralys Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #872 holding.
  • T. Rowe Price Associates first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • T. Rowe Price Associates's Mineralys Therapeutics position peaked at $48.1M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.